ENDOCAN LEVEL IN PATIENTS WITH CHRONIC KIDNEY DISEASE
DOI:
https://doi.org/10.31082/1728-452X-2020-221-222-11-12-35-42Keywords:
chronic kidney disease, cardiovascular disease, glomerular filtration rate, biomarkers, endocanAbstract
The relevance of the work is due to the high prevalence of chronic kidney disease (CKD) among the population and high mortality from cardiovascular disease (CVD) in this population. In this connection, it is necessary to search for new biomarkers in order to early identify individuals with cardiovascular risk in patients with CKD.
The purpose of this study to assess the endocan level in patients with CKD depending on the glomerular filtration rate (GFR), to study the relationship between the endocan level and other cardiovascular risk factors in patients with CKD.
Material and methods. 153 respondents with various stages of CKD were examined. The study included socio-demographic, anthropometric data, blood pressure measurements, cholesterol, high density lipoprotein (HDL), triglycerides (TG), glucose and endocan. Data analysis was performed using the statistical software package SPSS 22.
Results and discussion. The respondents in the groups did not differ in such indicators as gender, age, marital status, frequency of active smoking, diabetes, body mass index (BMI). Significant differences were found in the level of education (p=0.04), income (p=0.008), systolic pressure (SBP) (p=0.0001) and diastolic blood pressure (DBP) (p=0.0001). Levels of total cholesterol (cholesterol), (p=0.0001), uric acid (p=0.0001), cystatin C (p=0.0001) and endocan (p=0.0001) also had significant differences depending on GFR.
Conclusion. A comparative analysis of the frequency of “traditional” cardiovascular risk factors among patients with various stages of CKD showed the absence of differences in the frequency of active smoking, diabetes mellitus, obesity and the presence of significant differences in blood pressure and total cholesterol (p = 0.0001). Evaluation of the endocan level depending on the stage of CKD showed that with the progression of CKD, the endocan level increases significantly (p = 0.0001), which may indicate the progression of endothelial dysfunction with impaired renal function. Further studies are needed to determine the prognostic value of endocan in the development of cardiovascular events in patients with CKD.
References
Valerie A, Marcello T, John W. The global burden of kidney disease and the sustainable development goals. Bulletin of the World Health Organization. 2018;96(6):69-440. PMID: 29904224, DOI: 10.2471 / BLT.17.206441
Fox C, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis of individuals. Lancet. 2012;380(9854):1662-16732. DOI: 10.1016 / S0140-6736 (12) 61350-6
Cozzolino M, Mangano M, Stucchi A, et. al. Cardiovascular disease in dialysis patients. Nephrology Dialysis Transplantation. 2018;33(3):28–34. DOI: 10.1093/ndt/gfy174
Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrology Dialysis Transplantation. 2005;20(6):1048–1056. PMID: 15814534, DOI: 10.1093/ndt/gfh813
Carrero J, Jager D, Verduijn M, et al. Cardiovascular and noncardiovascular mortality among men and women starting dialysis. Clinical journal of the American Society of Nephrology. 2011;6(7):1722-30. DOI: 10.2215/CJN.11331210
Kobalava JD, Villevalde SV, Efremovceva МА. Osnovy kardiorenalnoi meditsiny [Fundamentals of Cardiorenal Medicine]. GEOTAR – Media; 2014:10-38
Wong C, Kwok C, Narain A, et. al. Marital status and risk of cardiovascular diseases: a systematic review and meta-analysis. Heart. 2018;104(23):1937-1948. DOI: 10.1136 / heartjnl-2018-313005
Berezin A. Biologicheskie marker kardiovascularnyh zabolevanyi [Biological markers of cardiovascular disease. A guide for doctors. In 3 parts]. Kyiev: Моrion; 2014;20-60
Dhingra R, Vasan R. Biomarkers in Cardiovascular Disease: Statistical Assessment and Section on Key Novel Heart Failure Biomarkers. Trends Cardiovascular Medicine. 2017;27(2):123–133. DOI: 10.1016/j.tcm.2016.07.005
Pareek M, Bhatt DL, Vaduganathan M, et al. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. European Journal of Preventive Cardiology. 2017;24(15):1648-1659. DOI: 10.1177/2047487317717065
Balta S, Mikhailidis D, Demirkol S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease. Atherosclerosis. 2015;243(1):339-43. DOI: 10.1016/j.atherosclerosis.2015.09.030
Yilmaz M, Siriopol D, Saglam M, et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86(6):1213-20. DOI: 10.1038/ki.2014.227
Yaya L, Yaqiong Zh, Weiya Sh, et al. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients With Type 2 Diabetes Mellitus. American Journal of the Medical Sciences. 2017;353(5):433-438. PMID: 28502328. DOI: 10.1016/j.amjms.2017.02.004
Baris Afsar, Mumtaz Takir, Osman Kostek. Endocan: A New Molecule Playing a Role in the Development of Hypertension and Chronic Kidney Disease? Journal of clinical hypertension. 2014;16(12):914-916. PMID: 25376269. DOI: 10.1111/jch.12440
Cakirca M, Dae SA, Zorlu M, et. al. The relationship between the atherosclerotic cardiovascular disease risk score used in the prediction of cardiovascular disease risk and endocan. Nigerian Journal of Clinical Practice. 2019;5:713-717. DOI: 10.4103/njcp.njcp_616_18
Musialowska D, Zbroch E, Koc-Zorawska E, et. al. Endocan Concentration in Patients With Primary Hypertension. Angiology. 2018;69(6):483-489. DOI: 10.1177/0003319717736158
Çelik M, Sökmen E, Sivri S, et. al. The Relationship Between Serum Endocan Level and Aortic Elastic Properties in Patients With Newly Diagnosed Essential Hypertension. Angiology. 2019;70(7):662-668. DOI: 10.1177/0003319718823625
ESC/ESH Arterial Hypertension (Management of) Guidelines ESC Clinical Practice Guidelines Published in 2018. Available from: https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/ Arterial-Hypertension-Management-of
WHO. Obesity and overweight. Available from: https://www. who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight
Jdanova TV, Borzunova NS, Nazarov AV. Features of lipid metabolism in patients with chronic kidney disease and the effect of lipid-lowering drugs on renal hemodynamics. Aterescleroz i dislypidemii = Atherosclerosis and Dyslipidemia. 2014;4:5-13 (In Russ.)
Gai ZH, Wang T, Visentin M. Lipid Accumulation and Chronic Kidney Disease. Nutrients. 2019;11(4):1-21. DOI: 10.3390/ nu11040722
